Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 4;20(2):1113–1120. doi: 10.3892/mmr.2019.10329

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zheng et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Effects of EA upon administration of WIN 55,212-2 or SR141716 on the behavioral tests of morphine-induced hyperalgesia. On day-1 (1 day before IT administration) and on days 1, 3, 5 and 7 after drug administration in rats that received IT normal saline, IT morphine, IT morphine + EA at ST36-GB34, IT morphine + EA treatment + CB1 agonist WIN 55,212-2 or IT morphine + EA treatment + CB1 antagonist SR141716, (A) mechanical hyperalgesia and (B) thermal hyperalgesia were assessed by electronic von Frey filament and hot plate, respectively. Data are expressed as the mean ± standard deviation (n=8 rats/group for mechanical hyperalgesia test and n=8 rats/group for thermal hyperalgesia test). *P<0.05 vs. the C group, ^#P<0.05 vs. the M group, ^##P<0.01 vs. the M group, ^&P<0.05 vs. the ME group. IT, intrathecal; EA, electroacupuncture; CB1, cannabinoid receptor 1; C, control; M, chronic morphine; ME, morphine + EA at ST36-GB34; MEW, the morphine + EA treatment + CB1 agonist WIN 55,212-2 group; MES, the morphine + EA treatment + CB1 antagonist SR141716 group.